Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥15.93 |
52 Week High | CN¥26.98 |
52 Week Low | CN¥13.63 |
Beta | 1.04 |
11 Month Change | 10.93% |
3 Month Change | -8.92% |
1 Year Change | -32.84% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -48.78% |
Recent News & Updates
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Recent updates
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Shareholder Returns
301211 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 5.0% | -1.1% | -0.6% |
1Y | -32.8% | -11.9% | -19.0% |
Return vs Industry: 301211 underperformed the CN Pharmaceuticals industry which returned -11.9% over the past year.
Return vs Market: 301211 underperformed the CN Market which returned -19% over the past year.
Price Volatility
301211 volatility | |
---|---|
301211 Average Weekly Movement | 6.1% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 301211 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301211's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 1,012 | Qun Liang | www.biocause.com |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Fundamentals Summary
301211 fundamental statistics | |
---|---|
Market cap | CN¥4.52b |
Earnings (TTM) | CN¥173.57m |
Revenue (TTM) | CN¥607.80m |
26.4x
P/E Ratio7.5x
P/S RatioIs 301211 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301211 income statement (TTM) | |
---|---|
Revenue | CN¥607.80m |
Cost of Revenue | CN¥352.26m |
Gross Profit | CN¥255.54m |
Other Expenses | CN¥81.97m |
Earnings | CN¥173.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | 0.60 |
Gross Margin | 42.04% |
Net Profit Margin | 28.56% |
Debt/Equity Ratio | 0% |
How did 301211 perform over the long term?
See historical performance and comparison